

SENATE BILL NO. 14

BY SENATOR BERNARD

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

AN ACT

To amend and reenact R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1) through (8), (12), (17) through (22), and (24) through (29) and (Schedule V)(D)(6), to enact R.S. 40:964(Schedule I)(A)(100) and (E)(14) through (16), (Schedule IV)(B)(58), and (Schedule V)(D)(7) and 989.1(C)(2)(nn), and to repeal R.S. 40:964(Schedule IV)(C), relative to the Uniform Controlled Dangerous Substances Law; to add certain substances to Schedules I, IV, and V; to remove substances from Schedule IV; to provide for updated structural language; to provide for unlawful hallucinogenic plants; and to provide for related matters.

Be it enacted by the Legislature of Louisiana:

Section 1. R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1) through (8), (12), (17) through (22), and (24) through (29) and (Schedule V)(D)(6) are hereby amended and reenacted and R.S. 40:964(Schedule I)(A)(100) and (E)(14) through (16), (Schedule IV)(B)(58), and (Schedule V)(D)(7) and 989.1(C)(2)(nn) are hereby enacted to read as follows:

§964. Composition of schedules

Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S. 40:962, consist of the following drugs or other substances, by whatever official name, common or usual name, chemical name, or brand name designated:

SCHEDULE I

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, or salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

* * *

1 (100) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)
2 piperazin-1-yl]-1-phenylpropan-2-ol)

3 * * *

4 E. Stimulants. Unless specifically excepted, or contained within a
5 pharmaceutical product approved by the United States Food and Drug
6 Administration, or unless listed in another schedule, any material, compound,
7 mixture, or preparation which contains any quantity of the following substances
8 having a stimulant effect on the central nervous system including its salts, isomers,
9 esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such
10 salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible
11 within the specific chemical designation:

12 (1) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the
13 following ways:

14 (i) By substitution ~~in~~ on the phenyl ring to any extent with an alkyl, hydroxyl
15 alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further
16 substituted ~~in~~ on the phenyl ring by one or more other univalent substituents.

17 * * *

18 (iii) By substitution at the 2-amino nitrogen atom with alkyl, cycloalkyl,
19 dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen
20 atom in a cyclic structure.

21 * * *

22 (8) Naphthylpyrovalerone whether or not further substituted ~~in~~ on the
23 naphthyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide
24 substituents, whether or not further substituted ~~in~~ on the naphthyl ring by one or
25 more other univalent substituents or whether or not further substituted ~~in~~ on the
26 carbon chain at the 3, 4, or 5 position with an alkyl substituent.

27 * * *

28 (14) Amineptine (7-[(10,11-dihydro-5H-dibenzo
29 [a,d]cyclohepten-5-yl)amino]heptanoic acid)

30 (15) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-

1,2,3-oxadiazol-3-ium-5-yl)carbamimidate)(16) Methiopropamine (N-methyl-1-(thiophen-2-yl)propane-2-amine)

F. Synthetic cannabinoids. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following individual compounds or chemical groups, or any of those individual compounds or groups which contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible within the specific compounds or chemical groups:

(1) Adamantoylindoles: any compound containing a 3-(1-adamantoyl)indole structure, whether or not further substituted ~~in~~ on the indole ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any extent.

(2) Adamantylamidoindoles: Any compound containing a N-(adamantyl)-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any extent.

(3) Benzoylindoles: any compound containing a 3-(benzoyl)indole structure, whether or not substituted ~~in~~ on the indole ring to any extent or **whether or not substituted on** the phenyl ring to any extent.

(4) Benzylindolecarboxamides: Any compound containing a N-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole ring or **whether not substituted on** the phenyl ring to any extent.

(5) Butaldehydeamidoindoles: Any compound containing a N-(1-oxobutan-2yl)-1H-indole-3-carboxamide structure, with or without substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, ~~alkylarylhalide, cycloalkylmethyl,~~ **arylalkylhalide, cycloalkylmethyl,** cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, **halide,** morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a

1 tetrahydropyranylmethyl group, whether or not further substituted on the
2 butaldehyde group to any extent.

3 (6) Cumylindolecarboxamides: Any compound containing a
4 N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without
5 substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
6 halide, ~~alkylarylhalide, cycloalkylmethyl,~~ arylalkylhalide, cycloalkylmethyl,
7 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide,
8 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
9 tetrahydropyranylmethyl group, whether or not further substituted on the phenyl
10 group to any extent.

11 (7) Cyclohexylphenols: any compound containing a 2-(3-
12 hydroxycyclohexyl)phenol structure, whether or not substituted ~~in~~ on the cyclohexyl
13 ring to any extent or whether or not substituted on the phenyl ring to any extent.

14 (8) Cyclopropanoylindoles: any compound containing a 3-
15 (cyclopropanoyl)indole structure, whether or not substituted ~~in~~ on the indole ring to
16 any extent or whether or not substituted on the cyclopropyl ring to any extent.

17 * * *

18 (12) Hexahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic
19 ring system to any extent except where contained in cannabis or cannabis resin.

20 * * *

21 (17) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole
22 structure, whether or not substituted ~~in~~ on the indole ring to any extent or whether
23 or not substituted on the naphthyl ring to any extent.

24 (18) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole
25 structure, whether or not substituted ~~in~~ on the pyrrole ring to any extent or whether
26 or not substituted on the naphthyl ring to any extent.

27 (19) Naphthylamidoindoles: any compound containing a N-(naphthyl)-1H-
28 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole
29 ring to any extent or whether or not substituted ~~in~~ on the naphthyl ring to any extent.

30 (20) Naphthylindolecarboxylates: Any compound containing a

1 naphthyl-1H-indole-3-carboxylate structure, whether or not further substituted ~~in~~ on
2 the indole ring or whether or not substituted on the naphthyl ring to any extent.

3 (21) Naphthylmethylenes: any compound containing a 1-(1-
4 naphthylmethyl)indene structure, whether or not substituted ~~in~~ on the indene ring to
5 any extent or whether or not substituted on the naphthyl ring to any extent.

6 (22) Naphthylmethyloindoles: any compound containing a 1-H-indol-3-yl-(1-
7 naphthyl)methane structure, whether or not substituted ~~in~~ on the indole ring to any
8 extent or whether or not substituted on the naphthyl ring to any extent.

9 * * *

10 (24) Phenylacetylindoles: any compound containing a 3-phenylacetylindole
11 structure, whether or not substituted ~~in~~ on the indole ring to any extent or whether
12 or not substituted on the phenyl ring to any extent.

13 (25) Phenylindolecarboxamides: Any compound containing a
14 N-phenyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~
15 on the indole ring or whether or not substituted on the phenyl ring to any extent.

16 (26) Phenylpropionaldehydeamidoindoles: Any compound containing a
17 N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without
18 substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
19 halide, ~~alkylarylhalide, cycloalkylmethyl,~~ arylalkylhalide, cycloalkylmethyl,
20 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide,
21 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
22 tetrahydropyranylmethyl group, whether or not further substituted on the
23 phenylpropionaldehyde group to any extent.

24 (27) Quinolinyndolecarboxamides: Any compound containing a N-
25 quinolinyl-1H-indole-3-carboxamide or N-isoquinolinyl-1H-indole-3-carboxamide
26 structure, whether or not further substituted ~~in~~ on the indole, quinoline or the
27 isoquinoline ring to any extent.

28 (28) Quinolinyndolecarboxylates: any compound containing a
29 quinolin-8-yl-1H-indole-3-carboxylate or isoquinolin-8-yl-1H-indole-3-carboxylate
30 structure, whether or not further substituted ~~in~~ on the indole, quinoline, or

1 isoquinoline ring to any extent.

2 (29) Tetrahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic
3 ring system to any extent except where contained in cannabis or cannabis resin.

4 * * *

5 SCHEDULE IV

6 * * *

7 B. Depressants.

8 Unless specifically excepted or unless listed in another schedule, any
9 material, compound, mixture, or preparation containing any quantity of the following
10 substances, including its salts, isomers, and salts of isomers, whenever the existence
11 of such salts, isomers, and salts of isomers is possible within the specific chemical
12 designation:

13 * * *

14 (58) Daridorexant

15 * * *

16 SCHEDULE V

17 * * *

18 D. Depressants. Unless specifically exempted or excluded or unless listed in
19 another schedule, any material, compound, mixture, or preparation which contains
20 any quantity of the following substances having a depressant effect on the central
21 nervous system, including its salts:

22 * * *

23 (6) ~~Pregalin~~ Pregabalin

24 (7) Ganaxolone (3- α -hydroxy-3- β -methyl-5- α -pregnan-20-one)

25 * * *

26 §989.1. Unlawful production, manufacture, distribution, or possession of
27 hallucinogenic plants; exceptions

28 * * *

29 C. For the purposes of this Section:

30 * * *

1 (2) "Hallucinogenic plant" means any part or portion of any of the
2 following:

3 * * *

4 **(nn) Amanita pantherina.**

5 * * *

6 Section 2. R.S. 40:964(Schedule IV)(C) is hereby repealed.

7 Section 3. The Louisiana State Law Institute is hereby authorized and directed to
8 renumber the substances in R.S. 40:964(Schedule I)(A), (C), and (E), (Schedule IV)(B), and
9 (Schedule V)(D) to ensure that the substances are in alphabetical order.

PRESIDENT OF THE SENATE

SPEAKER OF THE HOUSE OF REPRESENTATIVES

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____